Paul Dent

Researchers Laurence Booth, Jane L. Roberts, and others discuss GZ17-6.02's efficacy in killing uveal melanoma cells. They cover the compound's components, safety evaluations, phase I trials, interactions with inhibitors, and its impact on cell signals for tumor cell elimination.

Researchers investigate GZ17-6.02 compound in killing multiple myeloma cells. Study shows efficacy against inhibitor-resistant cells. Synergistic effects with proteasome inhibitors on key cell death pathways. Podcast explores potential of GZ17-6.02 in cancer treatment.

Researchers discuss the effectiveness of GZ17-6.02 in killing Mycosis Fungoides cells by activating various signaling pathways and inducing mitochondrial dysfunction